Date: 2017-01-25
Type of information: Loan
Company: Sensorion (France)
Investors: Bpifrance (France) Occitania region (France)
Amount: €950,000
Funding type: loan
Planned used:
- The purpose of this funding is to strengthen the Sensorion preclinical platform by implementing High Content Screening (HCS) approaches, focused on discovering new drugs for inner-ear disorders. Sensorion’s platform has already generated 3 first-in-class orally active drug candidates targeting inner-ear disorders: bouts of vertigo, with the SENS-111 compound (Phase 2); sudden sensorineural hearing loss, with the SENS-401 compound (Phase 1); ototoxicity, with the SENS-300 program (preclinical). The HCS approach will add higher throughput phenotypic capacity for screening new molecules, and will enable further detailed studies of their properties and impact on new therapeutic targets in the inner ear.
Others:
- • On January 25, 2017, Sensorion announced that Bpifrance and the Occitania region of Southern France have selected to support the Company via a €950,000 interestfree innovation loan (PTZI1) after a competitive selection process.
Therapeutic area: Otorhinolaryngology
Is general: Yes
